英诺特: 北京英诺特生物技术股份有限公司第二届监事会第十次会议决议公告

Meeting Overview - The second meeting of the Supervisory Board of Beijing Innotech Biotechnology Co., Ltd. was held on August 27, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1]. Financial Reporting - The Supervisory Board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results [2]. - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, affirming that it truthfully represents the situation [2]. Fund Management - The board approved the use of up to RMB 300 million of temporarily idle raised funds for cash management, ensuring it does not affect normal operations or project plans [3]. - The board also approved the use of up to RMB 1.7 billion of temporarily idle self-owned funds for purchasing safe and liquid financial products, maintaining operational safety [5]. Stock Incentive Plan - The board approved an adjustment to the grant price of the 2023 restricted stock incentive plan from RMB 13.20 per share to RMB 12.65 per share, confirming the adjustment's appropriateness and compliance with regulations [6]. - The board approved the 2025 restricted stock incentive plan and its summary, which aligns with relevant laws and is expected to benefit the company's sustainable development [10]. Capital Changes - The board approved a proposal to change the registered capital and cancel the Supervisory Board, transferring its powers to the Audit Committee, pending shareholder approval [7]. - The board approved the use of part of the surplus raised funds for other investment projects and project delays, aligning with market changes and operational needs [8]. Risk Management - The board discussed the purchase of directors and officers liability insurance, which will be submitted for shareholder approval due to the absence of effective resolutions [12].